An Open Phase III, Multi-centre 52-week, Parallel-group Study Evaluating the Safety and Efficacy of Formoterol 18 microg Daily Dose Compared With Standard COPD Treatment, in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

An Open Phase III, Multi-centre 52-week, Parallel-group Study Evaluating the Safety and Efficacy of Formoterol 18 microg Daily Dose Compared With Standard COPD Treatment, in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Formoterol (Primary) ; Antiasthmatics
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Registrational
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 17 Jan 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top